Brian Cheng
Stock Analyst at JP Morgan
(3.09)
# 2,663
Out of 5,182 analysts
79
Total ratings
45.45%
Success rate
2.07%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintains: Overweight | $65 → $91 | $66.82 | +36.19% | 3 | Apr 17, 2026 | |
| ALLO Allogene Therapeutics | Upgrades: Neutral | n/a | $2.25 | - | 6 | Apr 16, 2026 | |
| XNCR Xencor | Downgrades: Neutral | $18 → $13 | $13.10 | -0.76% | 6 | Mar 24, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $95 → $106 | $98.51 | +7.60% | 7 | Mar 19, 2026 | |
| TARA Protara Therapeutics | Initiates: Overweight | $27 | $4.99 | +441.08% | 1 | Mar 4, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Overweight | $29 | $8.74 | +231.81% | 1 | Mar 2, 2026 | |
| TGTX TG Therapeutics | Maintains: Overweight | $49 → $46 | $35.38 | +30.02% | 1 | Feb 2, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $92 → $122 | $131.67 | -7.34% | 2 | Feb 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $70 → $125 | $86.68 | +44.21% | 1 | Dec 10, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.20 | - | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $12 → $5 | $13.04 | -61.66% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $23 | $28.56 | -19.47% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.21 | - | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $4.85 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $33 | $28.62 | +15.30% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $27.85 | -28.19% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $50.99 | +37.28% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.96 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $23.49 | -6.34% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $23.37 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.89 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $8.99 | +267.07% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.49 | +304.04% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $850 → $700 | $4.51 | +15,421.06% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.76 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $320 → $96 | $7.93 | +1,110.59% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.06 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.35 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $8.30 | +924.10% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $8.90 | +135.96% | 1 | Aug 3, 2021 |
CG Oncology
Apr 17, 2026
Maintains: Overweight
Price Target: $65 → $91
Current: $66.82
Upside: +36.19%
Allogene Therapeutics
Apr 16, 2026
Upgrades: Neutral
Price Target: n/a
Current: $2.25
Upside: -
Xencor
Mar 24, 2026
Downgrades: Neutral
Price Target: $18 → $13
Current: $13.10
Upside: -0.76%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Overweight
Price Target: $95 → $106
Current: $98.51
Upside: +7.60%
Protara Therapeutics
Mar 4, 2026
Initiates: Overweight
Price Target: $27
Current: $4.99
Upside: +441.08%
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $29
Current: $8.74
Upside: +231.81%
TG Therapeutics
Feb 2, 2026
Maintains: Overweight
Price Target: $49 → $46
Current: $35.38
Upside: +30.02%
Revolution Medicines
Feb 2, 2026
Maintains: Overweight
Price Target: $92 → $122
Current: $131.67
Upside: -7.34%
Kymera Therapeutics
Dec 10, 2025
Maintains: Overweight
Price Target: $70 → $125
Current: $86.68
Upside: +44.21%
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.20
Upside: -
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $13.04
Upside: -61.66%
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $28.56
Upside: -19.47%
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.21
Upside: -
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $4.85
Upside: -
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $28.62
Upside: +15.30%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $27.85
Upside: -28.19%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $50.99
Upside: +37.28%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $3.96
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $23.49
Upside: -6.34%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $23.37
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.89
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $8.99
Upside: +267.07%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.49
Upside: +304.04%
Sep 25, 2023
Maintains: Overweight
Price Target: $850 → $700
Current: $4.51
Upside: +15,421.06%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.76
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $320 → $96
Current: $7.93
Upside: +1,110.59%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.06
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.35
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $8.30
Upside: +924.10%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $8.90
Upside: +135.96%